All In Biotech

Drug Trial Radar · NCT01919697

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of Plecanatide in Patients With Chronic Idiopathic Constipation (CIC)

Last checked: Nov 20, 2026Latest source record: Jul 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,370

Actual

Start

Aug 2013

Primary completion

Jan 2016

Study completion Mar 2016

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Aug 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 81 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).

Conditions

  • Chronic Idiopathic Constipation

Interventions

  • PlecanatideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: From first dose up to 72 weeks
  2. Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of PlecanatideTime frame: From first dose up to 72 weeks
  3. Summary of Vital Signs at >Day 364 - Blood Pressure (Systolic and Diastolic; mmHg)Time frame: From first dose up to 72 weeks
  4. Summary of Vital Signs at >Day 364 - Heart Rate (Beats Per Minute)Time frame: From first dose up to 72 weeks
  5. Summary of Vital Signs at >Day 364 - Body Temperature (°C)Time frame: From first dose up to 72 weeks
  6. Summary of Vital Signs at >Day 364 - Respiration Rate (Breaths Per Minute)Time frame: From first dose up to 72 weeks
  7. Summary of ECG Results Shift From Baseline at > Day 364Time frame: From first dose up to 72 weeks
  8. Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From BaselineTime frame: From first dose up to 72 weeks

Locations

220 sites in 2 countries. Site status is shown where the registry gives one.

  • Synergy Research Site

    Birmingham, Alabama

  • Synergy Research Site

    Dothan, Alabama

  • Synergy Research Site

    Gulf Shores, Alabama

  • Synergy Research Site

    Huntsville, Alabama

  • Synergy Research Site

    Chandler, Arizona

  • Synergy Research Site

    Phoenix, Arizona

  • Synergy Research Site

    Tempe, Arizona

  • Synergy Research Site

    Tucson, Arizona

  • Synergy Research Site

    Tucson, Arizona

  • Synergy Research Site

    Tucson, Arizona

  • Synergy Research Site

    Little Rock, Arkansas

  • Synergy Research Site

    North Little Rock, Arkansas

  • Synergy Research Site

    Anaheim, California

  • Synergy Research Site

    Anaheim, California

  • Synergy Research Site

    Artesia, California

  • Synergy Research Site

    Carlsbad, California

  • Synergy Research Site

    Cerritos, California

  • Synergy Research Site

    Chula Vista, California

  • Synergy Research Site

    Corona, California

  • Synergy Research Site

    Encinitas, California

  • Synergy Research Site

    Fountain Valley, California

  • Synergy Research Site

    Fresno, California

  • Synergy Research Site

    Hawaiian Gardens, California

  • Synergy Research Site

    La Mirada, California

  • Synergy Research Site

    Laguna Hills, California

  • Synergy Research Site

    Lancaster, California

  • Synergy Research Site

    Long Beach, California

  • Synergy Research Site

    Los Angeles, California

  • Synergy Research Site

    Los Angeles, California

  • Synergy Research Site

    Mission Hills, California

  • Synergy Research Site

    North Hollywood, California

  • Synergy Research Site

    Orange, California

  • Synergy Research Site

    Pasadena, California

  • Synergy Research Site

    Sacramento, California

  • Synergy Research Site

    San Diego, California

  • Synergy Research Site

    San Diego, California

  • Synergy Research Site

    San Diego, California

  • Synergy Research Site

    Thousand Oaks, California

  • Synergy Research Site

    Colorado Springs, Colorado

  • Synergy Research Site

    Colorado Springs, Colorado

Showing 40 of 220 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.